Paclitaxel (C47H51NO14), a chemotherapy drug from the Himalayan Yew (Taxus wallichiana), is costly due to destructive harvesting. This project aims to induce paclitaxel biosynthesis in the needles through two parts. A gene gun will introduce an engineered plasmid containing both a CaMV 35S promoter — which drives gene expression in the cytosol to stimulate production of paclitaxel and its precursors such as TASY — and the genes DBAT, BAPT, and DBTNBT, which have been identified as rate determining enzymes. This approach offers a more efficient and cost-effective alternative to traditional extraction while reducing harm done to the tree, promoting its population.